Roland Gamsjaeger

Dr. Roland Gamsjaeger

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
RGRoland Gamsjaeger
Roland Gamsjaeger
CLC Liew
C Liew
FLF Loughlin
F Loughlin
MCM Crossley
M Crossley
JMJ Mackay
J Mackay

2 May 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JLJanine M. Lamonica
Janine M. Lamonica
WDWulan Deng
Wulan Deng
SKStephan Kadauke
Stephan Kadauke
ACAmy E. Campbell
Amy E. Campbell
RGRoland Gamsjaeger
Roland Gamsjaeger
GBGerd A. Blobel
Gerd A. Blobel
Acetylation of histones triggers association with bromodomain-containing proteins that regulate diverse chromatin-related processes. Although acetylation of transcription factors has been appreciated for some time, the mechanistic consequences are less well understood. The hematopoietic transcription factor GATA1 is acetylated at conserved lysines that are required for its stable association with chromatin. We show that the BET family protein Brd3 binds via its first bromodomain (BD1) to GATA1 in an acetylation-dependent manner in vitro and in vivo. Mutation of a single residue in BD1 that is involved in acetyl-lysine binding abrogated recruitment of Brd3 by GATA1, demonstrating that acetylation of GATA1 is essential for Brd3 association with chromatin. Notably, Brd3 is recruited by GATA1 to both active and repressed target genes in a fashion seemingly independent of histone acetylation. Anti-Brd3 ChIP followed by massively parallel sequencing in GATA1-deficient erythroid precursor cells and those that are GATA1 replete revealed that GATA1 is a major determinant of Brd3 recruitment to genomic targets within chromatin. A pharmacologic compound that occupies the acetyl-lysine binding pockets of Brd3 bromodomains disrupts the Brd3-GATA1 interaction, diminishes the chromatin occupancy of both proteins, and inhibits erythroid maturation. Together these findings provide a mechanism for GATA1 acetylation and suggest that Brd3 “reads” acetyl marks on nuclear factors to promote their stable association with chromatin.

1 November 2001 in Biophysical Journal
Verified
Journal Article
Closed access
GHGregory S. Harms
Gregory S. Harms
LCLaurent Cognet
Laurent Cognet
PLPiet H.M. Lommerse
Piet H.M. Lommerse
GBGerhard A. Blab
Gerhard A. Blab
HKHeike Kahr
Heike Kahr
TSThomas Schmidt
Thomas Schmidt

1 July 2011 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
RGRoland Gamsjaeger
Roland Gamsjaeger
SWSarah R. Webb
Sarah R. Webb
JLJanine M. Lamonica
Janine M. Lamonica
ABAndrew Billin
Andrew Billin
GBGerd A. Blobel
Gerd A. Blobel
JMJoel P. Mackay
Joel P. Mackay
Recent data demonstrate that small synthetic compounds specifically targeting bromodomain proteins can modulate the expression of cancer-related or inflammatory genes. Although these studies have focused on the ability of bromodomains to recognize acetylated histones, it is increasingly becoming clear that histone-like modifications exist on other important proteins, such as transcription factors. However, our understanding of the molecular mechanisms through which these modifications modulate protein function is far from complete. The transcription factor GATA1 can be acetylated at lysine residues adjacent to the zinc finger domains, and this acetylation is essential for the normal chromatin occupancy of GATA1. We have recently identified the bromodomain-containing protein Brd3 as a cofactor that interacts with acetylated GATA1 and shown that this interaction is essential for the targeting of GATA1 to chromatin. Here we describe the structural basis for this interaction. Our data reveal for the first time the molecular details of an interaction between a transcription factor bearing multiple acetylation modifications and its cognate recognition module. We also show that this interaction can be inhibited by an acetyllysine mimic, highlighting the importance of further increasing the specificity of compounds that target bromodomain and extraterminal (BET) bromodomains in order to fully realize their therapeutic potential.

1 November 2011 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
NSNatalie J. Saez
Natalie J. Saez
MMMehdi Mobli
Mehdi Mobli
MBMichael Bieri
Michael Bieri
ICIrène R. Chassagnon
Irène R. Chassagnon
AMAlpeshkumar K. Malde
Alpeshkumar K. Malde
Glenn KingGlenn King
Glenn King
Acid-sensing ion channel 1a (ASIC1a) is a primary acid sensor in the peripheral and central nervous system. It has been implicated as a novel therapeutic target for a broad range of pathophysiological conditions including pain, ischemic stroke, depression, and autoimmune diseases such as multiple sclerosis. The only known selective blocker of ASIC1a is π-TRTX-Pc1a (PcTx1), a disulfide-rich 40-residue peptide isolated from spider venom. π-TRTX-Pc1a is an effective analgesic in rodent models of acute pain and it provides neuroprotection in a mouse model of ischemic stroke. Thus, understanding the molecular basis of the π-TRTX-Pc1a–ASIC1a interaction should facilitate development of therapeutically useful ASIC1a blockers. We therefore developed an efficient bacterial expression system to produce a panel of π-TRTX-Pc1a mutants for probing structure-activity relationships as well as isotopically labeled toxin for determination of its solution structure and dynamics. We demonstrate that the toxin pharmacophore resides in a β-hairpin loop that was revealed to be mobile over a wide range of time scales using molecular dynamics simulations in combination with NMR spin relaxation and relaxation dispersion measurements. The toxin-receptor interaction was modeled by in silico docking of the toxin structure onto a homology model of rat ASIC1a in a restraints-driven approach that was designed to take account of the dynamics of the toxin pharmacophore and the consequent remodeling of side-chain conformations upon receptor binding. The resulting model reveals new insights into the mechanism of action of π-TRTX-Pc1a and provides an experimentally validated template for the rational design of therapeutically useful π-TRTX-Pc1a mimetics.

7 April 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
FLFionna E. Loughlin
Fionna E. Loughlin
RMRobyn E. Mansfield
Robyn E. Mansfield
PVPaula M. Vaz
Paula M. Vaz
AMAaron P. McGrath
Aaron P. McGrath
SSSurya Setiyaputra
Surya Setiyaputra
JMJoel P. Mackay
Joel P. Mackay
The alternative splicing of mRNA is a critical process in higher eukaryotes that generates substantial proteomic diversity. Many of the proteins that are essential to this process contain arginine/serine-rich (RS) domains. ZRANB2 is a widely-expressed and highly-conserved RS-domain protein that can regulate alternative splicing but lacks canonical RNA-binding domains. Instead, it contains 2 RanBP2-type zinc finger (ZnF) domains. We demonstrate that these ZnFs recognize ssRNA with high affinity and specificity. Each ZnF binds to a single AGGUAA motif and the 2 domains combine to recognize AGGUAA(N x )AGGUAA double sites, suggesting that ZRANB2 regulates alternative splicing via a direct interaction with pre-mRNA at sites that resemble the consensus 5′ splice site. We show using X-ray crystallography that recognition of an AGGUAA motif by a single ZnF is dominated by side-chain hydrogen bonds to the bases and formation of a guanine-tryptophan-guanine “ladder.” A number of other human proteins that function in RNA processing also contain RanBP2 ZnFs in which the RNA-binding residues of ZRANB2 are conserved. The ZnFs of ZRANB2 therefore define another class of RNA-binding domain, advancing our understanding of RNA recognition and emphasizing the versatility of ZnF domains in molecular recognition.